296 Results
Sort By:
Published on January 4, 2024
A rare type of T immune cell can help predict which patients may benefit most from cancer immunotherapies, a new study has found. The study was published in Nature Cancer and led by researchers from King’s College London, Guy’s and St Thomas’ Hospital Trust, and the Francis Crick Institute. “Checkpoint inhibition (CPI),…
Published on January 3, 2024
SimBioSys, which specializes in spatial biophysics and artificial intelligence (AI), has recently entered into a strategic collaboration with Mayo Clinic to advance digital precision medicine solutions for breast cancer patients. The collaboration will develop cloud-based clinical software tools that will guide the decision-making process for early-stage breast cancer patients, covering…
Published on December 20, 2023
Damian Doherty sat down with Cancer Research Institute (CRI) CEO Jill O’Donnell-Tormey, PhD, to discuss the organization’s most recent progress, and perspectives on the future of cancer immunotherapy research and development. With 12 immunotherapies having been approved by the U.S. Food and Drug Administration since July 2022, including the first approval…
Published on December 20, 2023
Life is like the changing of seasons, each uniquely beautiful. Just as autumn leaves fall to the ground and make way for winter’s gentle snow, life has transformational cycles. The cycle of life continues through the changing seasons, like how the autumn winds strip the trees of their leaves and…
Published on December 20, 2023
A multi-institution collaboration has shown that embedding a class of medical imaging dyes called aminocyanines in cell membranes and inducing a rapid vibration will kill cancer cells. The research from investigators at Rice University, the University of Texas MD Anderson Cancer Center, and Texas A&M University, was published in Nature…
Published on December 18, 2023
Sponsored content brought to you by Identifying tumor biomarkers and characterizing their function in cancer cells help provide valuable data to guide the development and selection of personalized therapies and treatment plans for patients that may improve health outcomes and survivorship. The pace of innovation in precision medicine testing technologies…
Published on November 29, 2023
BRAF mutated pediatric gliomas respond better to combination targeted therapy than chemotherapy, data just published in The New England Journal of Medicine affirms. The researchers found combination targeted therapy lessened chemotherapy side effects, improved overall response rate by more than four-fold, and increased median progression free survival from 7.4 months…
Published on November 29, 2023
University of Chicago researchers have identified a nutrient derived from beef, lamb, and dairy products that could enhance cancer therapies. Hao Fan and co-authors report in Nature that the long-chain fatty acid trans-vaccenic acid (TVA) promotes the tumor-infiltrating and cytotoxic functions of CD8+ T cells and “has high translational potential…
Published on November 13, 2023
Researchers at Virginia Commonwealth University have discovered a new way of using a synthetic double-stranded RNA for the treatment of pancreatic ductal adenocarcinoma (PDAC), an aggressive type of pancreatic cancer. As the most common form of pancreatic cancer, 95% of all pancreatic cancers are diagnosed as PDAC. It is also…
Published on October 25, 2023
Adding immunotherapy to chemotherapy almost doubled survival in patients with an advanced type of bladder cancer, in the first of its kind trial reported in The New England Journal of Medicine and at the annual meeting of the European Society for Medical Oncology (ESMO). The multicenter, international study was co-led by Mount Sinai…
Published on October 18, 2023
Immunotherapies such as checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapies have revolutionized the field of oncology over the last few years, but they are just the beginning. A new wave of immunotherapies is now hitting the clinic. In 2022, Immunocore’s tebentafusp (Kimmtrak) was the first TCR anti-cancer therapy…
Published on October 12, 2023
Researchers at the University of California, Los Angeles (UCLA) have developed a new treatment method using a nanocapsule to deliver the enzyme lactate oxidase into solid tumors, improving anti-tumoral immune response and immune checkpoint inhibitor therapy efficacy.Reporting in Science Translational Medicine, scientists are targeting lactate—a chemical produced by cancer cells…
Published on October 11, 2023
Researchers at the University of Texas at Austin (UT) have developed a drug able to restore the effectiveness of immune cells fighting cancer, slowing tumor growth, and increasing lifespan in mouse models of melanoma, bladder cancer, leukemia, and colon cancer. One of the most prevalent genetic abnormalities observed in multiple…
Published on October 10, 2023
Bristol Myers Squibb (BMS) has signed a $4.8 billion deal to buy Mirati Therapeutics and its cancer drug KRAZATI, which targets KRAS. In December 2022, KRAZATI (adagrasib) was granted accelerated U.S. Food and Drug Administration (FDA) approval for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic Non-Small…
Published on October 4, 2023
Immune checkpoint blockade (ICB) is an estimated $35B+ market already with multiple cancer indication approvals, but to date, neoadjuvant ICB therapy is only FDA-approved in non-small-cell (NSC) lung cancer and triple-negative breast cancer. This fact masks the huge potential, in both the clinic and research lab, of this class of…